Transgene: Cash position in line with expectations

Fair Value EUR21 (+147%)       CORPORATE
News published on October Friday 19, 2012
Share on

ANALYSIS

  • Transgene has released its Q3 financial report with revenues of EUR3.4m while cash burn stood at EUR12.5m during the quarter. Over the first nine months, consumption of cash therefore amounted to EUR30.6m. Transgene continues to expect cash burn of EUR50m over 2012 with an increase in Q4 as clinical trial expenses go up.
  • The group's cash position was EUR108.9m at end-September 2012.
VALUATION
  • We derive a FV of EUR21 via a SOTP valuation
NEXT CATALYSTS
  • H1 2013: Phase II results for JX594/TG6006
  • H1 2013: Phase IIb results for TG4010
Mathieu Chabert, mchabert@bryangarnier.com

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities